AU2001228320A1 - Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection - Google Patents

Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection

Info

Publication number
AU2001228320A1
AU2001228320A1 AU2001228320A AU2832001A AU2001228320A1 AU 2001228320 A1 AU2001228320 A1 AU 2001228320A1 AU 2001228320 A AU2001228320 A AU 2001228320A AU 2832001 A AU2832001 A AU 2832001A AU 2001228320 A1 AU2001228320 A1 AU 2001228320A1
Authority
AU
Australia
Prior art keywords
ctl
mhc
identified
relates
epitopes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001228320A
Inventor
Soren Brunak
Soren Buus
Sylvie Corbet
Anders Fomsgaard
Jan Hansen
Sanne Lise Lauemoller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Publication of AU2001228320A1 publication Critical patent/AU2001228320A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to the identification of CTL epitopes by the combination of biochemical assays, statistical matrix calculations, and artificial neural networks. A set of peptide libraries are used to generate complete unbiased matrices representing peptide-MHC interactions used to generate a primary prediction of MHC binding for all possible non-redundant peptides. The best binders are subject to a quantitative biochemical binding assay and subsequently a computerised artificial neural network prediction program built from these in vitro experimental MHC-I binding data. The method further comprises improving the identified epitope by replacing amino acids, and testing the identified CTL epitopes in in vitro and in vivo models. Thus, one aspect of the invention relates to the identification of a CTL component of a vaccine and the development of said CTL component. Another aspect of the invention relates to the identified epitopes of said CTL component.
AU2001228320A 2000-01-28 2001-01-29 Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection Abandoned AU2001228320A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00610017 2000-01-28
EP00610017 2000-01-28
US17933300P 2000-01-31 2000-01-31
US60179333 2000-01-31
PCT/DK2001/000059 WO2001055177A2 (en) 2000-01-28 2001-01-29 Methods to identify ctl epitopes of hiv

Publications (1)

Publication Number Publication Date
AU2001228320A1 true AU2001228320A1 (en) 2001-08-07

Family

ID=56290104

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001228320A Abandoned AU2001228320A1 (en) 2000-01-28 2001-01-29 Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection

Country Status (6)

Country Link
EP (1) EP1250351B1 (en)
JP (1) JP2003523365A (en)
AT (1) ATE311404T1 (en)
AU (1) AU2001228320A1 (en)
CA (1) CA2397998A1 (en)
WO (1) WO2001055177A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003297155B2 (en) * 2002-12-16 2010-03-18 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant vaccine viruses expressing IL-15 and methods of using the same
EP1589030A1 (en) * 2004-04-14 2005-10-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Bob-1 specific T cells and methods to use
DE602005008264D1 (en) * 2004-10-04 2008-08-28 Biovaxim Ltd SUB-TYPE-ASSISTED INACTIVATED WHOLE VIRUS VACCINE FOR THE TREATMENT OF PATIENTS WITH HIV INFECTION
ES2573105T3 (en) 2006-03-10 2016-06-06 Peptcell Limited Peptide sequences and compositions
WO2007137591A2 (en) * 2006-06-01 2007-12-06 Statens Serum Institut Hiv vaccine
ES2788863T3 (en) * 2010-05-14 2020-10-23 Massachusetts Gen Hospital Compositions of tumor-specific neoantigens for use in treating tumors
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
CN106456724A (en) 2013-12-20 2017-02-22 博德研究所 Combination therapy with neoantigen vaccine
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
WO2016100975A1 (en) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
TWI806815B (en) 2015-05-20 2023-07-01 美商博德研究所有限公司 Shared gata3-related tumor-specific neoantigens
EP3574116A1 (en) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
AU2018266705B2 (en) 2017-05-08 2023-05-04 Gritstone Bio, Inc. Alphavirus neoantigen vectors
WO2019126186A1 (en) 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Neoantigens and uses thereof
CA3140019A1 (en) 2019-05-30 2020-12-03 Gritstone Bio, Inc. Modified adenoviruses
WO2021003348A1 (en) * 2019-07-02 2021-01-07 Gritstone Oncology, Inc. Hiv antigens and mhc complexes
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes

Also Published As

Publication number Publication date
JP2003523365A (en) 2003-08-05
WO2001055177A2 (en) 2001-08-02
CA2397998A1 (en) 2001-08-02
WO2001055177A3 (en) 2002-03-07
EP1250351B1 (en) 2005-11-30
ATE311404T1 (en) 2005-12-15
EP1250351A2 (en) 2002-10-23

Similar Documents

Publication Publication Date Title
AU2001228320A1 (en) Hiv peptides and nucleic acids encoding them for diagnosis and control of hiv infection
Bhasin et al. SVM based method for predicting HLA-DRB1* 0401 binding peptides in an antigen sequence
Zhao et al. Application of support vector machines for T-cell epitopes prediction
Andreatta et al. NNAlign: a web-based prediction method allowing non-expert end-user discovery of sequence motifs in quantitative peptide data
WO2003099999A3 (en) Generation and selection of protein library in silico
CA2497496A1 (en) In vitro peptide expression library
PT1309861E (en) FUNCTIONAL ARRAYS OF PROTEINS
DE69434578D1 (en) Expression vectors encoding bispecific proteins, and methods of producing biologically active bispecific fusion proteins in mammalian cells
DK2230303T3 (en) Isolation of biological modulators from biodiversity gene fragment libraries
EP0832207B1 (en) A method for identification of biologically active peptides and nucleic acids
D’Ambrosio et al. Comparative proteomic analysis of mammalian animal tissues and body fluids: bovine proteome database
ATE311443T1 (en) METHODS FOR SCREENING PROTEINS
AU2001245011B2 (en) System and method for systematic prediction of ligand/receptor activity
WO2005010023A3 (en) Method for prediction of an epitope
Yu et al. Synthesis of a Glycopeptide Vaccine Conjugate for Induction of Antibodies Recognizing O‐Mannosyl Glycopeptides
WO2002072863A8 (en) Methods for large scale protein matching
WO2003020005A3 (en) Lp mammalian proteins; related reagents
AP2368A (en) Novel expression vectors and uses thereof.
WO2002074906A3 (en) Lp mammalian proteins; related reagents
Kumar et al. Immunoinformatics: where immunology meets bioinformatics
Miklos et al. The evolution of protein domains and the organizational complexities of metazoans
Williams et al. High-throughput optimisation of protein secretion in yeast via an engineered biosensor
US20010053523A1 (en) Method for identification of biologically active peptides and nucleic acids
JP2002529075A5 (en)
Meyer et al. Public T-cell epitopes shared among SARS-CoV-2 variants are presented on prevalent HLA class I alleles